AcuFocus is a technology company.
AcuFocus is dedicated to innovation in ophthalmic surgery, providing advanced solutions for cataract and refractive procedures.
AcuFocus has raised $39.0M across 2 funding rounds.
AcuFocus has raised $39.0M in total across 2 funding rounds.
# AcuFocus: Ophthalmic Medical Device Pioneer
AcuFocus is an ophthalmic medical device company that designs and manufactures small-aperture intraocular lenses (IOLs) to improve vision outcomes for cataract patients[1][2]. The company's flagship product, the IC-8 Apthera IOL, uses patented pinhole technology to deliver continuous depth of focus across near, intermediate, and far distances without the visual disturbances common in traditional multifocal lenses[2][3].
Founded in 2001 and based in Irvine, California, AcuFocus addresses a significant unmet need in cataract surgery: providing patients with high-quality vision at multiple distances while minimizing halo, glare, and contrast sensitivity loss[2]. The company generated approximately $40 million in annual revenue as of 2024 and operates with a lean team of 35 employees[3]. In January 2023, AcuFocus was acquired by Bausch & Lomb UK, integrating its breakthrough technology into a larger ophthalmic ecosystem[1].
AcuFocus was established in 2001 with a focused mission: to develop small-aperture optics for vision correction[1]. The company's journey reflects a deliberate evolution from concept to clinical validation. Its first device, the KAMRA, received U.S. regulatory approval in April 2015, marking the company's entry into the market[4]. This early success validated the core technology platform and provided the foundation for developing more advanced applications.
The breakthrough came with the IC-8 IOL, which received CE mark approval in Europe in 2015 and FDA approval in the United States in July 2022[1][4]. By the time of FDA clearance, AcuFocus had accumulated extensive clinical data on approximately 200 patients, demonstrating the safety and efficacy of its small-aperture approach[4]. This methodical, evidence-based path to market differentiated AcuFocus in a competitive ophthalmic device landscape.
AcuFocus operates within the premium cataract surgery market, where demand for advanced IOLs continues to grow as aging populations seek better vision outcomes. The company's technology addresses a critical gap: patients increasingly reject traditional monofocal lenses (which provide clear distance vision only) and are wary of multifocal lenses due to visual side effects[4].
The timing of AcuFocus's FDA approval in 2022 coincided with rising adoption of premium IOL technologies and growing surgeon interest in alternatives to multifocal designs. By positioning itself as a solution that delivers multifocal-like functionality without multifocal drawbacks, AcuFocus tapped into a market shift toward patient-centric outcomes.
The company's acquisition by Bausch & Lomb—a major global ophthalmic player—signals the strategic value of small-aperture technology within the broader medtech ecosystem. This integration accelerates market penetration and distribution while validating the technology's clinical and commercial potential.
AcuFocus represents a focused innovation success story in medical devices: a company that spent two decades perfecting a single, elegant technological approach and achieved meaningful clinical validation before scaling. The IC-8's market adoption will likely depend on surgeon education, reimbursement dynamics, and patient awareness—areas where Bausch & Lomb's distribution network provides significant advantage.
Looking ahead, the company's influence will grow as cataract surgeons increasingly adopt small-aperture IOLs as a preferred premium option. Future opportunities may include expanding indications beyond cataract surgery, developing next-generation small-aperture designs, and exploring international markets where the technology has already gained CE mark approval[3]. The broader lesson: in medtech, sustained focus on solving a specific clinical problem—rather than chasing market trends—can yield transformative products.
AcuFocus has raised $39.0M in total across 2 funding rounds.
AcuFocus's investors include Pivotal bioVenture Partners, Versant Ventures.
AcuFocus has raised $39.0M across 2 funding rounds. Most recently, it raised $21.0M Series G in September 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2014 | $21.0M Series G | Pivotal bioVenture Partners, Versant Ventures | |
| Jan 1, 2007 | $18.0M Series D | Pivotal bioVenture Partners, Versant Ventures |